THU0152 WHO ARE THE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHO ARE GETTING COMORBIDITY SCREENING PROCEDURES IN ACCORDANCE WITH GUIDELINES
Objectives: to characterise patients who are being screened correctly (i.e., in accordance with recommendations).
Methods: Study design:
This was an open long-term (3 years) extension of the COMEDRA 6 month randomized controlled trial in which patients with definite, stable RA were visiting a nurse for comorbidity assessment and screening counselling.
[3] For this analysis, only the final visit data were used crosssectionally. Assessment of comorbidity screening: A score was developed to quantify comorbidity screening procedures in accordance with guidelines: [4] this score gives 50 points to CV risk screening, 20 points to cancer screening, 20 points to pneumococcus and influenza vaccination and 10 points to osteoporosis screening. The score ranges 0-100 and 0 indicates optimal screening. Factors associated with optimal screening: demographic and disease characteristics were compared between patients considered well-screened (lowest tertile for screening score) versus other patients. Statistical analysis: Variables with p<0.20 in univariate analysis were entered into the multivariate analysis using a backward stepwise logistic regression. Results: 769 patients were assessed: mean (±SD) age 62 (±11) years, mean disease duration 17 (±10) years; 614 (80%) were women and 535 (70%) were receiving a biologic. Disease was well-controlled (mean DAS28 2.8±1.3). The mean comorbidity screening score was 24.3 (±17.8) (range, 0-100). The 316 patients (41% of all patients) in the lowest tertile for this score (i.e., with a score ≤15) were less often smokers: odds ratio [95% confidence interval] 0.45 [0.28 -0.72], were more often treated for hyperlipidemia (2.58 [1.85 -3 .61]), and were more often treated with a biologic (1.97 [1.4 -2.76]). Conclusions: Comorbidity screening is suboptimal in RA. Patients who were better screened were more frequently already followed-up for hyperlipidemia and were more frequently receiving biologics but more less frequently smokers. Thus it seems getting optimal screening may reflect both patient characteristics but also physician attention to comorbidity in certain situations. Empowering patients to be responsible for the comorbidity screening reminders should be explored. Background: RA patients have a higher risk of vascular events, especially cardiac ones. Besides, mortality in these patients is 54% higher than the general population. Nowadays, we have non-invasive techniques that allow us to detect subclinical vascular damage. Objectives: To describe subclinical vascular affection in a sample of RA patients and to explore its relationship with mortality and with the development of vascular events. Methods: Ambispective observational study with analytical components. We included, consecutively, RA patients controlled in a tertiary hospital. We gathered demographic (sex, age, body mass index [BMI]), clinical (traditional vascular risk factors, previous vascular events), and analytical variables (atherogenic index, glomerular filtration [GF] [MDRD], CRP, ESR). Other variables were collected retrospectively from the electronic medical record. We estimated the modified SCORE. We explored the extracranial branches of the carotid artery with an Esaote MyLab70XVG ultrasound device with a linear probe (7-12mHz) and an automated program measuring intima media thickness (IMT) by radiofrequency ("Quality intima media thickness in real-time, QIMT"), and the presence of atheroma plaques, as per the Mannheim consensus, was registered. We also determined pulse wave velocity (PWV) by a validated MobilOGraph ® device. We considered an IMT>900 μand a PWV≥10m/s as pathologic values. We prospectively collected mortality and the development of new vascular events over three years. Statistical analysis was performed using SPSS 17.0 software. Results: We included 198 patients, excluding 13 because of previous vascular events. The mean age was 65,8 years (DE 13,3) and most of them were women (76,2%). The mean BMI was 27,29 (DE 4, 84) . 27% were smokers, 42,7% hypertensive, 46,7% dyslipemic and 10,8% were diabetic. The mean duration of RA was 17,37 years. 74,6% of patients were seropositive (RF and/or ACPA) and 75, 5% had erosions. 74,6% received glucocorticoids, 58,4% NSAIDs, 98,9% DMARDs and 35,7% biologic therapies. The mean CRP and ESR were 9,45mg/L (DE: 32,2) and 14,04mm/h (DE:14,46), respectively. The mean modified SCORE was 1,81 (DE: 1,79). Regarding the vascular study, 48,6% of the patients had atheroma plaques, 31,7% had a pathologic PWV with a mean value of 9,13 (DE 2,12), and 16,7% had a pathologic IMT with a mean value of 754 μ(DE 168,52). During 3 years of follow up, we registered 26 (14,1%) vascular events: 9,7% cardiac, 2,1% cerebral and 2,2% peripheral. There were 5 deaths: 3 vascular, 1 infectious and 1 respiratory. The development of vascular events was related with the presence of atheroma plaques (p 0,008) and with pathologic PWV (p 0,028), as well as with the presence of erosions, GF, HTA and dyslipidemia. The appearance of cardiac events was related, also, with the use of NSAID (p 0,041 Background: Patients with rheumatoid arthritis (RA) are at increased cardiovascular risk with contribution of both inflammation and traditional risk factors. Dyslipidemia is an important risk factor and lipid-lowering therapy plays a key role in cardio-preventive treatment. A new class of low density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors are now emerging. In view of a lower rate of musculoskeletal side effects these drugs might be preferred over statins in patients with RA. Active inflammation in RA leads to a decline in lipid levels, but the relation between inflammation and PCSK9 levels is unknown. Objectives: To assess PSCK9 levels in RA patients, and the relationship with lipid levels and disease activity. Methods: PSCK9 levels were assessed using ELISA in 97 randomly selected patients. Lipid profile assessment comprised TC, HDL-C, LDL-C and triglycerides. Disease activity was assessed using disease activity score of 28 joints (DAS28). Results: The mean age of RA patients was 54.5 years (± 10.8) and they were predominantly female (74.2% Conclusions: PCSK9 levels in RA are similar to the general population. RA patients with active disease had higher PCSK9 levels compared to patients with low disease activity. Altogether, PCSK9 inhibitors could be an alternative treatment for dyslipidemia in RA patients who experience side effects of statins, albeit that a formal trial still has to be conducted in this category of patients. Background: The overall assessment of patients with systemic arthritis can not exclude comorbidities, which may impact therapeutic outcomes. Objectives: To assess the impact of baseline modified rheumatic disease comorbidity index 1 (mRDCI) on drug survival and effectiveness of biological drugs in patients affected with Rheumatoid arthritis (RA), Spondyloarthritis (SpA), and Psoriatic Arthritis (PsA) in real-world settings. Methods: Patients (nr. 635) with RA (nr. 214), SpA (nr. 213), and PsA (nr. 208) starting a biological drug were retrospectively analysed. mRDCI was scored at baseline, and disease characteristics were recorded at entry and at last observation. Drug retention was analysed using Kaplan-Meier curves. Cox-regression models were used to estimate the association of mRDCI with drug discontinuation and clinical outcomes, the achievement of clinical remission based on 28 joint-Disease Activity Score (DAS28) <2.6 for RA and PsA, and on Ankylosing Spondylitis-C-reactive protein Disease Activity Score (ASDAS-CRP) <1.3 for SpA. Results: Baseline mRDCI significantly correlated with the number of biological drug switches (rho 0.47). Drug persistence was significantly higher in patients with mRDCI=0 (96.4%), than in those with mRDCI ≥2 (83.9%). Compared to mRDCI ≥2 patients, those without comorbidities showed significantly higher drug survival rate in PsA (p=0.0001) or SpA (p=0.02), but not in RA (Figure 1 ). mRDCI was also found to be a predictor of definitive drug discontinuation (HR 1.53) and of failure to achieve DAS28 based remission in RA (HR 0.66) or PsA (HR 0.77), and ASDAS-CRP driven remission in SpA (HR 0.43). 13 (2.0) 5 (2.4) 7 (3.3) 1 (0.5) 6 9 (1.4) 2 (1.0) 6 (2.8) 1 (0.5) 7 9 (1.4) 2 (1.0) 3 (1.4) 4 (1.9) 8 3 (0.5) 1 (0.5) 1 (0.5) 1 (0.5)
Values are the mean 1 SD unless otherwise indicated. BMI = Body Mass Index; mRDCI = modified Rheumatic Diseases Comorbidity Index.
Conclusions:
This study provided evidence that baseline mRDCI negatively impacts the persistence on biologic treatments and the clinical outcomes in patients with RA, SpA, and PsA in real-life settings. 
